

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7325924

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THE P.F. LABORATORIES, INC.	04/08/2019
PURDUE PHARMA TECHNOLOGIES, INC.	04/08/2019
RECEIVING PARTY DATA	
Name:	PURDUE PHARMA L.P.
Street Address:	ONE STAMFORD FORUM
City:	STAMFORD
State/Country:	CONNECTICUT
Postal Code:	06901-3431
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16900600
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2023712600
Email:	bhsu@sternekessler.com, vballen@sternekessler.com
Correspondent Name:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
Address Line 1:	1100 NEW YORK AVENUE, N.W.
Address Line 4:	WASHINGTON, D.C. 20005
ATTORNEY DOCKET NUMBER:	1861.467000H
NAME OF SUBMITTER:	MATTHEW S. BODENSTEIN
SIGNATURE:	/Matthew S. Bodenstein/
DATE SIGNED:	05/11/2022
Total Attachments: 9	
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page1.tif	
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page2.tif	
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page3.tif	
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page4.tif	
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page5.tif	

source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page6.tif
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page7.tif
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page8.tif
source=1861467000H-Assignment-PF Labs and PP Technologies to Purdue Pharma LP#page9.tif

Exhibit A

ASSIGNMENT

Effective as of April 8, 2019 (the "Effective Date"), each of The P.F. Laboratories, Inc., a New Jersey corporation, having a place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford Connecticut 06901 ("PF"); and Purdue Pharma Technologies, Inc., a Delaware corporation, having a place of business at One Stamford Forum, Stamford Connecticut 06901 ("PPTI") (PF and PPTI are referred to individually as an "Assignor" and collectively as the "Assignors") for good and valuable consideration, the sufficiency of which and receipt of which are hereby acknowledged, does hereby irrevocably, sell, assign, transfer, convey and deliver to Purdue Pharma L.P., a Delaware limited partnership, having a place of business at One Stamford Forum, 201 Tresser Boulevard, Stamford Connecticut 06901 (hereinafter "Assignee"), its successors and assigns, all of such Assignor's right, title, and interest in and to the patents and patent applications set forth on Schedule 1 attached hereto and all (i) divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations and the equivalents of any of the foregoing, (ii) rights to the inventions disclosed in any of the foregoing, (iii) patents or patent applications that claim priority or are foreign counterparts of any of the foregoing and (iv) rights to assert, claim or sue and collect damages, costs and expenses for the past, present or future infringement, misappropriation or other violation of any of the foregoing; in each case of (i), (ii), (iii) and (iv), in any jurisdiction or territory, said interest, being the entire ownership interest in the same currently held by each Assignor, to be held and enjoyed by Assignee, its successors, assigns, and legal representatives, to the full extent of their term thereof, as fully and entirely as the same would have been held and enjoyed by each Assignor if this assignment and sale had not been made.

Each Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority to issue any Letters Patent resulting from these applications to Assignee.

This Assignment shall be governed by and construed in accordance with the laws of the State of Delaware without regard to the conflicts of law principles thereof.

[The remainder of this page has been intentionally left blank; the next pages are the signature pages.]

IN WITNESS WHEREOF, the parties hereto, through their authorized representatives,
have caused this Assignment to be duly executed and delivered as of the Effective Date.

THE P.F. LABORATORIES, INC.

By: 


Name: Edward Mahony

Title: Executive Vice President

STATE OF Connecticut)
) ss
COUNTY OF Fairfield)


On the 8 day of April, 2019, before me personally came
Edward Mahony, who is personally known to me on the basis of satisfactory evidence to
be the individual whose name is subscribed to the within instrument and did depose and say to
me that he or she executed the same in his or her capacity as E.V.P. of
The P.F. Labs, the entity described in and which executed the foregoing instrument, and that
he or she executed and delivered said instrument pursuant to authority given by the board of
directors of such entity (or other applicable authority of such entity).

FRANCESCA DeBIASE
NOTARY PUBLIC OF CONNECTICUT
Comm. # 163524
My Commission Expires 2/28/2023


Notary Public


(PLACE STAMP AND SEAL ABOVE)


PURDUE PHARMA TECHNOLOGIES, INC.

By: 
Name: Edward Mahony
Title: Executive Vice President

STATE OF Connecticut)
COUNTY OF Fairfield) ss

On the 8 day of April, 2019, before me personally came Edward Mahony, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as E.V.P. of Purdue Pharma Tech, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).



FRANCESCA DeBIASE
NOTARY PUBLIC OF CONNECTICUT
Comm. # 163524
My Commission Expires 2/28/2023


Notary Public

(PLACE STAMP AND SEAL ABOVE)

PURDUE PHARMA L.P.


By: Purdue Pharma Inc., its general partner

By: 
Name: Jon Lowne
Title: SVP, Chief Financial Officer

STATE OF Connecticut)
COUNTY OF Fairfield) ss

On the 8 day of April, 2019, before me personally came Jon Lowne, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as SVP, CFO of Purdue Pharma, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

FRANCESCA DeBIASE
NOTARY PUBLIC OF CONNECTICUT
Comm. # **163524**
My Commission Expires **2/28/2023**


Notary Public

(PLACE STAMP AND SEAL ABOVE)

Schedule I
PF Labs and PPTI Assignment

#	App Title	Application Number	Patent No.
1	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	60/310,434	
2	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	10/214,412	
3	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	12/262,015	8,389,007
4	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	12/653,115	
5	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	13/349,449	8,337,888
6	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	13/726,324	9,060,976
7	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	13/765,368	9,040,084
8	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	13/890,874	9,308,170
9	Pharmaceutical Formulation Containing Gelling Agent	13/905,922	8,609,683
10	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	13/905,931	8,529,948
11	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	13/946,418	8,999,961
12	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/243,580	
13	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/255,502	8,871,265
14	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/460,134	9,034,376
15	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/460,170	
16	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/470,631	
17	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	14/470,662	
18	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/484,077	9,044,435
19	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/605,034	
20	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/610,156	9,308,171
21	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/611,716	
22	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/638,685	9,867,783
23	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/658,285	9,387,173
24	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/728,601	
25	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/730,002	
26	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/730,003	
27	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/730,016	
28	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/730,017	
29	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/730,021	
30	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/733,654	
31	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/733,654	
32	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/733,654	
33	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/733,634	
34	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/733,647	

Schedule 1
PF Labs and PPTI Assignment

#	App Title	Application Number	Patent No.
35	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/733,659	
36	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/846,021	
37	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/851,575	9,387,174
38	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/851,727	9,517,207
39	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/852,157	
40	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/852,236	
41	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/856,386	
42	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/856,388	
43	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/856,392	
44	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	14/856,394	
45	Pharmaceutical Formulation Containing Gelling Agent	15/013,628	10,071,057
46	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/015,708	
47	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/015,722	9,693,961
48	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/015,735	9,872,836
49	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/015,763	10,076,497
50	Pharmaceutical Formulation Containing Gelling Agent	15/015,769	9,861,582
51	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/019,195	9,867,784
52	Pharmaceutical Formulation Containing Gelling Agent	15/019,222	
53	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/019,281	10,064,824
54	Pharmaceutical Formulation Containing Gelling Agent	15/019,304	9,968,559
55	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/019,315	
56	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/019,321	
57	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/284,706	9,877,924
58	Pharmaceutical Formulation Containing Gelling Agent	15/284,711	9,757,341
59	Pharmaceutical Formulation Containing Gelling Agent	15/354,473	
60	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/354,538	9,861,583
61	Pharmaceutical Formulation Containing Gelling Agent	15/345,979	10,130,586
62	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/637,703	
63	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/702,127	10,064,825
64	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/803,370	10,206,881
65	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/877,917	
66	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	15/865,832	
67	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	16/121,242	
68	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	16/133,993	
69	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	16/163,076	
70	PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT	16/229,188	
71	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	60/310,537	

Schedule 1
PF Labs and PPTI Assignment

#	App Title	Application Number	Patent No.
72	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	10/214,413	7,842,307
73	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	12/909,527	8,524,275
74	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	13/956,467	9,101,668
75	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	14/793,174	9,561,225
76	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	15/384,229	9,808,453
77	PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT	15/724,869	
78	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	60/557,492	
79	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	60/601,534	
80	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	60/620,072	
81	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	60/648,625	
82	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	60/651,778	
83	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	11/093,626	7,129,248
84	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	11/391,897	
85	OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	11/653,530	7,674,798
86	OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	11/653,529	7,683,072
87	OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	11/653,531	7,674,799
88	OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	11/729,741	7,674,800
89	OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	12/380,800	
90	8A,14-DIHYDROXY-7,8-DIHYDROCODEINONE	12/711,948	8,822,687
91	OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	12/893,681	
92	OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE	13/366,755	9,073,933
93	PROCESS FOR PREPARING OXYCODONE SUBSTANTIALLY FREE OF 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	14/725,110	
94	OXYCODONE COMPOSITIONS	14/725,153	9,522,919
95	Oxycodone Compositions	14/725,210	
96	METHODS OF TREATING PAIN	15/058,379	
97	PROCESS FOR PREPARING OXYCODONE COMPOSITIONS	15/058,420	9,777,011
98	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/058,812	
99	PROCESS FOR PREPARING OXYCODONE COMPOSITIONS	15/058,912	
100	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/058,960	
101	PROCESS FOR PREPARING OXYCODONE COMPOSITIONS	15/058,390	
102	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/061,416	
103	PROCESS FOR PRAPARING OXYCODONE COMPOSITIONS	15/061,477	
104	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/061,541	
105	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/061,588	

Schedule 1
PF Labs and PPTI Assignment

#	App. Title	Application Number	Patent No.
106	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/061,640	
107	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/061,681	
108	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/061,733	
109	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/058,363	
110	PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PP, 14-HYDROXYCODEINONE AND COMPOSITIONS THEREOF	15/721,167	
111	PROCESS FOR PREPARING OXYCODONE COMPOSITIONS	16/262,683	
112	METHOD OF REDUCING ALPHA, BETA UNSATURATED KETONES IN OPIOID COMPOSITIONS	60/658,791	
113	METHOD OF REDUCING ALPHA, BETA UNSATURATED KETONES IN OPIOID COMPOSITIONS	11/885,402	7,939,543